Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements align with the provided FDA label excerpts (indication, mechanism, oral once-daily dosing, hypersensitivity including discontinuation). However, several adverse reaction and clinical efficacy statements are partially unsupported or overly specific vs the label (e.g., inclusion of diarrhea and upper respiratory tract infection as common, and the portrayal of hypersensitivity symptoms).
Category Scores
Accurate Statements
Qulipta (atogepant) is used for the preventive treatment of episodic migraine in adults.
Label excerpt 1 (INDICATIONS AND USAGE) states: “QULIPTA is indicated for the preventive treatment of migraine in adults.” The provided label text does not explicitly say episodic vs chronic in the indication section, but the overall label includes episodic migraine efficacy in Section 14.1.
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Label excerpt 12.1 (Mechanism of Action): “Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.”
Qulipta is taken orally.
Label excerpt 2.1: “QULIPTA is taken orally with or without food.”
Qulipta is taken typically once a day.
Label excerpt 2.1: “10 mg, 30 mg, or 60 mg taken once daily” and “60 mg taken once daily.”
Qulipta dosing options include 10 mg, 25 mg, and 50 mg or 60 mg depending on the specific product formulation and prescribed regimen.
Label excerpt 2.1 and 3 show recommended dosing of 10 mg, 30 mg, and 60 mg once daily and supplied strengths 10 mg/30 mg/60 mg. The claim includes additional strengths not present in the provided label excerpts.
Qulipta hypersensitivity reaction symptoms may include rash, itching, hives, or swelling of the face, mouth, tongue, or throat.
Label excerpt 5.1: “Hypersensitivity reactions, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema …” (partial symptom alignment; specifics beyond those listed are not supported in provided excerpts).
Serious side effects of Qulipta may include hypersensitivity reactions.
Label excerpt 5.1: “Hypersensitivity reactions, including anaphylaxis … have been reported … If a hypersensitivity reaction occurs, discontinue QULIPTA …”
Nausea, constipation, and diarrhea are among the most frequently reported side effects of Qulipta.
Partially supported: Label excerpt 6.1 states “The most common adverse reactions … are nausea, constipation, and fatigue/somnolence.” The label excerpt does not list diarrhea as one of the most common adverse reactions.
Clinical trials have demonstrated Qulipta's efficacy in reducing monthly migraine days compared to placebo.
Label excerpt 14.1 episodic migraine: Study 1/2 “greater mean decreases from baseline in MMD across the 12-week treatment period compared to patients who received placebo.”
Unsupported Statements
The most common side effects of Qulipta include nausea, constipation, diarrhea, fatigue, and upper respiratory tract infection.
Label excerpt 6.1 lists the most common adverse reactions as “nausea, constipation, and fatigue/somnolence.” It does not list diarrhea or upper respiratory tract infection as most common in the provided text.
Qulipta blocks the action of CGRP.
Label excerpt 12.1 states atogepant is a “CGRP receptor antagonist.” It does not explicitly state “blocks the action of CGRP” in the provided excerpts.
By inhibiting CGRP, Qulipta is believed to reduce the frequency of migraine attacks.
The provided excerpts state the mechanism as CGRP receptor antagonism and provide efficacy endpoints, but do not include the specific phrase/causal phrasing “inhibiting CGRP… believed to reduce frequency of migraine attacks.”
Qulipta hypersensitivity reaction symptoms may include rash, itching, hives, or swelling of the face, mouth, tongue, or throat.
Provided label excerpt 5.1 supports rash/pruritus/urticaria and facial edema, but does not explicitly mention mouth/tongue/throat swelling.
Individuals taking Qulipta may experience upper respiratory tract infections.
The provided label excerpts list common adverse reactions (nausea, constipation, fatigue/somnolence) and hypersensitivity; upper respiratory tract infection is not included in the provided excerpted adverse reactions list.
Qulipta dosing options include 10 mg, 25 mg, and 50 mg or 60 mg depending on the specific product formulation and prescribed regimen.
The provided label excerpts specify recommended episodic migraine doses of 10 mg, 30 mg, or 60 mg once daily and chronic migraine 60 mg once daily, and supplied strengths of 10/30/60 mg. No 25 mg or 50 mg (or 50/60 “depending on formulation”) appears in the provided excerpts.
Contradictions
Low
AI Statement
The most common side effects of Qulipta include nausea, constipation, diarrhea, fatigue, and upper respiratory tract infection.
Label Reference
6.1 Clinical Trials Experience: “The most common adverse reactions … are nausea, constipation, and fatigue/somnolence.”
Important Omissions
No boxed warning content was evaluated because the provided FDA label excerpts do not include any boxed warning section.
Importance:
Moderate
No mention of other adverse reactions described elsewhere in the label (e.g., hypertension, Raynaud’s phenomenon) beyond hypersensitivity and the partially listed common adverse reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Main safety-related content (hypersensitivity reactions and associated labeled items such as rash/pruritus/urticaria/facial edema) is broadly consistent, but adverse reaction specificity is weakened by unsupported claims (diarrhea and upper respiratory tract infection presented as most common; additional swelling sites not supported).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Adverse reaction assertions include diarrhea and upper respiratory tract infection as most common, and hypersensitivity symptom locations are more specific than provided in the label excerpts.
Suggested Improvement
Limit “most common” adverse reactions to those explicitly listed in the provided label excerpt (nausea, constipation, fatigue/somnolence). For hypersensitivity, use label-listed manifestations (rash, pruritus, urticaria, facial edema; dyspnea/rash/pruritus/urticaria/anaphylaxis) without adding mouth/tongue/throat swelling unless supported by additional label sections.